Research ExplorerPublicationsAllogeneic peripheral blood stem cell transplantation with a...

Allogeneic peripheral blood stem cell transplantation with anti-thymocyte globulin versus allogeneic bone marrow transplantation without anti-thymocyte globulin

Standard

Allogeneic peripheral blood stem cell transplantation with anti-thymocyte globulin versus allogeneic bone marrow transplantation without anti-thymocyte globulin. / Baron, Frédéric; Galimard, Jacques-Emmanuel; Labopin, Myriam; Yakoub-Agha, Ibrahim; Niittyvuopio, Riitta; Kroger, Nicolaus ; Griskevicius, Laimonas; Wu, Depei; Forcade, Edouard; Richard, Carlos; Aljurf, Mahmoud; Helbig, Grzegorz; Labussière-Wallet, Hélène; Mohty, Mohamad; Nagler, Arnon.

In: HAEMATOLOGICA, Vol. 105, No. 4, 04.2020, p. 1138-1146.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Baron, F, Galimard, J-E, Labopin, M, Yakoub-Agha, I, Niittyvuopio, R, Kroger, N, Griskevicius, L, Wu, D, Forcade, E, Richard, C, Aljurf, M, Helbig, G, Labussière-Wallet, H, Mohty, M & Nagler, A 2020, 'Allogeneic peripheral blood stem cell transplantation with anti-thymocyte globulin versus allogeneic bone marrow transplantation without anti-thymocyte globulin', HAEMATOLOGICA, vol. 105, no. 4, pp. 1138-1146. https://doi.org/10.3324/haematol.2019.227603

APA

Baron, F., Galimard, J-E., Labopin, M., Yakoub-Agha, I., Niittyvuopio, R., Kroger, N., Griskevicius, L., Wu, D., Forcade, E., Richard, C., Aljurf, M., Helbig, G., Labussière-Wallet, H., Mohty, M., & Nagler, A. (2020). Allogeneic peripheral blood stem cell transplantation with anti-thymocyte globulin versus allogeneic bone marrow transplantation without anti-thymocyte globulin. HAEMATOLOGICA, 105(4), 1138-1146. https://doi.org/10.3324/haematol.2019.227603

Vancouver

Baron F, Galimard J-E, Labopin M, Yakoub-Agha I, Niittyvuopio R, Kroger N et al. Allogeneic peripheral blood stem cell transplantation with anti-thymocyte globulin versus allogeneic bone marrow transplantation without anti-thymocyte globulin. HAEMATOLOGICA. 2020 Apr;105(4):1138-1146. https://doi.org/10.3324/haematol.2019.227603

Bibtex

@article{7a72e6533a91496f867492be5dc33de2,
title = "Allogeneic peripheral blood stem cell transplantation with anti-thymocyte globulin versus allogeneic bone marrow transplantation without anti-thymocyte globulin",
abstract = "We compared severe graft-versus-host-disease (GvHD) free and relapse-free survival and other transplantation outcomes of acute myeloid leukemia (AML) patients given bone marrow (BM) without anti-thymocyte globulin (ATG) versus peripheral blood stem cells (PBSC) with ATG after myeloablative conditioning. In the cohort of patients receiving grafts from a human leukocyte antigen (HLA)-matched sibling donor, patients given PBSC with ATG (n=1,021) and those given BM without ATG (n=1,633) presented comparable severe GvHD-free relapse-free survival (GRSF)(hazard ratio [HR]=0.9, 95% confidence interval [CI]: 0.8-1.1, P=0.5) and overall survival (HR=1.0, 95% CI: 0.8-1.2, P=0.8). They had however, a lower incidence of chronic GvHD (cGvHD) (HR=0.7, 95% CI: 0.6-0.9, P=0.01). In the cohort of patients receiving grafts from HLA-matched unrelated donor , patients given PBSC with ATG (n=2,318) had better severe GvHD-free and relapse-free survival (GRFS) than those given BM without ATG (n=303) (HR=0.8, 95% CI: 0.6-0.9, P=0.001). They also had a lower incidence of cGvHD (HR=0.6, 95% CI: 0.5-0.8, P=0.0006) and better overall survival (HR=0.8, 95% CI: 0.6-1.0, P=0.04). In summary, these data suggest that PBSC with ATG results in comparable (in the case of sibling donor) or significantly better (in the case of unrelated donor) severe GRFS than BM without ATG in patients with AML in complete remission receiving grafts after myeloablative conditioning.",
author = "Fr{\'e}d{\'e}ric Baron and Jacques-Emmanuel Galimard and Myriam Labopin and Ibrahim Yakoub-Agha and Riitta Niittyvuopio and Nicolaus Kroger and Laimonas Griskevicius and Depei Wu and Edouard Forcade and Carlos Richard and Mahmoud Aljurf and Grzegorz Helbig and H{\'e}l{\`e}ne Labussi{\`e}re-Wallet and Mohamad Mohty and Arnon Nagler",
note = "Copyright{\textcopyright} 2020 Ferrata Storti Foundation.",
year = "2020",
month = apr,
doi = "10.3324/haematol.2019.227603",
language = "English",
volume = "105",
pages = "1138--1146",
journal = "HAEMATOLOGICA",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "4",

}

RIS

TY - JOUR

T1 - Allogeneic peripheral blood stem cell transplantation with anti-thymocyte globulin versus allogeneic bone marrow transplantation without anti-thymocyte globulin

AU - Baron, Frédéric

AU - Galimard, Jacques-Emmanuel

AU - Labopin, Myriam

AU - Yakoub-Agha, Ibrahim

AU - Niittyvuopio, Riitta

AU - Kroger, Nicolaus

AU - Griskevicius, Laimonas

AU - Wu, Depei

AU - Forcade, Edouard

AU - Richard, Carlos

AU - Aljurf, Mahmoud

AU - Helbig, Grzegorz

AU - Labussière-Wallet, Hélène

AU - Mohty, Mohamad

AU - Nagler, Arnon

N1 - Copyright© 2020 Ferrata Storti Foundation.

PY - 2020/4

Y1 - 2020/4

N2 - We compared severe graft-versus-host-disease (GvHD) free and relapse-free survival and other transplantation outcomes of acute myeloid leukemia (AML) patients given bone marrow (BM) without anti-thymocyte globulin (ATG) versus peripheral blood stem cells (PBSC) with ATG after myeloablative conditioning. In the cohort of patients receiving grafts from a human leukocyte antigen (HLA)-matched sibling donor, patients given PBSC with ATG (n=1,021) and those given BM without ATG (n=1,633) presented comparable severe GvHD-free relapse-free survival (GRSF)(hazard ratio [HR]=0.9, 95% confidence interval [CI]: 0.8-1.1, P=0.5) and overall survival (HR=1.0, 95% CI: 0.8-1.2, P=0.8). They had however, a lower incidence of chronic GvHD (cGvHD) (HR=0.7, 95% CI: 0.6-0.9, P=0.01). In the cohort of patients receiving grafts from HLA-matched unrelated donor , patients given PBSC with ATG (n=2,318) had better severe GvHD-free and relapse-free survival (GRFS) than those given BM without ATG (n=303) (HR=0.8, 95% CI: 0.6-0.9, P=0.001). They also had a lower incidence of cGvHD (HR=0.6, 95% CI: 0.5-0.8, P=0.0006) and better overall survival (HR=0.8, 95% CI: 0.6-1.0, P=0.04). In summary, these data suggest that PBSC with ATG results in comparable (in the case of sibling donor) or significantly better (in the case of unrelated donor) severe GRFS than BM without ATG in patients with AML in complete remission receiving grafts after myeloablative conditioning.

AB - We compared severe graft-versus-host-disease (GvHD) free and relapse-free survival and other transplantation outcomes of acute myeloid leukemia (AML) patients given bone marrow (BM) without anti-thymocyte globulin (ATG) versus peripheral blood stem cells (PBSC) with ATG after myeloablative conditioning. In the cohort of patients receiving grafts from a human leukocyte antigen (HLA)-matched sibling donor, patients given PBSC with ATG (n=1,021) and those given BM without ATG (n=1,633) presented comparable severe GvHD-free relapse-free survival (GRSF)(hazard ratio [HR]=0.9, 95% confidence interval [CI]: 0.8-1.1, P=0.5) and overall survival (HR=1.0, 95% CI: 0.8-1.2, P=0.8). They had however, a lower incidence of chronic GvHD (cGvHD) (HR=0.7, 95% CI: 0.6-0.9, P=0.01). In the cohort of patients receiving grafts from HLA-matched unrelated donor , patients given PBSC with ATG (n=2,318) had better severe GvHD-free and relapse-free survival (GRFS) than those given BM without ATG (n=303) (HR=0.8, 95% CI: 0.6-0.9, P=0.001). They also had a lower incidence of cGvHD (HR=0.6, 95% CI: 0.5-0.8, P=0.0006) and better overall survival (HR=0.8, 95% CI: 0.6-1.0, P=0.04). In summary, these data suggest that PBSC with ATG results in comparable (in the case of sibling donor) or significantly better (in the case of unrelated donor) severe GRFS than BM without ATG in patients with AML in complete remission receiving grafts after myeloablative conditioning.

U2 - 10.3324/haematol.2019.227603

DO - 10.3324/haematol.2019.227603

M3 - SCORING: Journal article

C2 - 31413093

VL - 105

SP - 1138

EP - 1146

JO - HAEMATOLOGICA

JF - HAEMATOLOGICA

SN - 0390-6078

IS - 4

ER -